

2019 Future of Pruritus R&D Pipeline Drugs and Companies- Analysis of Global Pruritus Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2C0BC664989EN.html>

Date: January 2019

Pages: 85

Price: US\$ 2,199.00 (Single User License)

ID: 2C0BC664989EN

Abstracts

The global demand for Pruritus treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Pruritus pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Pruritus pipeline companies from advancing their products into Phase 3 or Phase 4.

Pruritus Report Description

The H1 2019 pipeline review report on Pruritus pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Pruritus pipeline compounds.

The Pruritus pipeline guide presents information on all active drugs currently being developed for Pruritus. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Pruritus

pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Pruritus drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Pruritus product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Pruritus pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Pruritus pipeline report includes

- An overview of Pruritus disease including symptoms, causes, diagnosis and available treatment options is provided.

- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

- Phase wise count of pipeline compounds

- Company wise list of pipeline compounds

- Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator,

Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Pruritus pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Pruritus pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Pruritus pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL PRURITUS PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Pruritus Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Pruritus pipeline, H1- 2019
- 3.5 Mechanism of Action wise Pruritus Pipeline Candidates

4. ALBIREO PHARMA INC PRURITUS PIPELINE DETAILS

- 4.1 Albireo Pharma Inc Business Profile
- 4.2 Albireo Pharma Inc Pruritus Drug Details
 - 4.2.1 Drug Snapshot
 - 4.2.1.1 Originator
 - 4.2.1.2 Collaborator/Co-Developer
 - 4.2.1.3 Route of Administration
 - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 4.2.1.5 Area
 - 4.2.1.6 Type of Molecular Entity
- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5. AMGEN INC PRURITUS PIPELINE DETAILS

- 5.1 Amgen Inc Business Profile
- 5.2 Amgen Inc Pruritus Drug Details
 - 5.2.1 Drug Snapshot
 - 5.2.1.1 Originator
 - 5.2.1.2 Collaborator/Co-Developer
 - 5.2.1.3 Route of Administration
 - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 5.2.1.5 Area
 - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6. AMOREPACIFIC CORP PRURITUS PIPELINE DETAILS

- 6.1 Amorepacific Corp Business Profile
- 6.2 Amorepacific Corp Pruritus Drug Details
 - 6.2.1 Drug Snapshot
 - 6.2.1.1 Originator
 - 6.2.1.2 Collaborator/Co-Developer
 - 6.2.1.3 Route of Administration
 - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 6.2.1.5 Area
 - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7. ANTALGENICS SL PRURITUS PIPELINE DETAILS

- 7.1 AntalGenics SL Business Profile
- 7.2 AntalGenics SL Pruritus Drug Details
 - 7.2.1 Drug Snapshot

- 7.2.1.1 Originator
- 7.2.1.2 Collaborator/Co-Developer
- 7.2.1.3 Route of Administration
- 7.2.1.4 Orphan Drug/Fast Track/Special Designation
- 7.2.1.5 Area
- 7.2.1.6 Type of Molecular Entity
- 7.3 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8. AOBIOME LLC PRURITUS PIPELINE DETAILS

- 8.1 AOBiome LLC Business Profile
- 8.2 AOBiome LLC Pruritus Drug Details
 - 8.2.1 Drug Snapshot
 - 8.2.1.1 Originator
 - 8.2.1.2 Collaborator/Co-Developer
 - 8.2.1.3 Route of Administration
 - 8.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 8.2.1.5 Area
 - 8.2.1.6 Type of Molecular Entity
- 8.3 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9. ASANA BIOSCIENCES LLC PRURITUS PIPELINE DETAILS

- 9.1 Asana BioSciences LLC Business Profile
- 9.2 Asana BioSciences LLC Pruritus Drug Details
 - 9.2.1 Drug Snapshot
 - 9.2.1.1 Originator
 - 9.2.1.2 Collaborator/Co-Developer
 - 9.2.1.3 Route of Administration
 - 9.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 9.2.1.5 Area

- 9.2.1.6 Type of Molecular Entity
- 9.3 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10. CARA THERAPEUTICS INC PRURITUS PIPELINE DETAILS

- 10.1 Cara Therapeutics Inc Business Profile
- 10.2 Cara Therapeutics Inc Pruritus Drug Details
 - 10.2.1 Drug Snapshot
 - 10.2.1.1 Originator
 - 10.2.1.2 Collaborator/Co-Developer
 - 10.2.1.3 Route of Administration
 - 10.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 10.2.1.5 Area
 - 10.2.1.6 Type of Molecular Entity
- 10.3 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11. CELGENE CORP PRURITUS PIPELINE DETAILS

- 11.1 Celgene Corp Business Profile
- 11.2 Celgene Corp Pruritus Drug Details
 - 11.2.1 Drug Snapshot
 - 11.2.1.1 Originator
 - 11.2.1.2 Collaborator/Co-Developer
 - 11.2.1.3 Route of Administration
 - 11.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 11.2.1.5 Area
 - 11.2.1.6 Type of Molecular Entity
- 11.3 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details

11.7 Latest Drug Developments

12. CHUGAI PHARMACEUTICAL CO LTD PRURITUS PIPELINE DETAILS

12.1 Chugai Pharmaceutical Co Ltd Business Profile

12.2 Chugai Pharmaceutical Co Ltd Pruritus Drug Details

12.2.1 Drug Snapshot

12.2.1.1 Originator

12.2.1.2 Collaborator/Co-Developer

12.2.1.3 Route of Administration

12.2.1.4 Orphan Drug/Fast Track/Special Designation

12.2.1.5 Area

12.2.1.6 Type of Molecular Entity

12.3 Current Status

12.4 Drug Overview

12.5 Drug Mechanism of Action

12.6 Clinical/Pre-clinical Trial Details

12.7 Latest Drug Developments

13. ELORAC INC PRURITUS PIPELINE DETAILS

13.1 ELORAC Inc Business Profile

13.2 ELORAC Inc Pruritus Drug Details

13.2.1 Drug Snapshot

13.2.1.1 Originator

13.2.1.2 Collaborator/Co-Developer

13.2.1.3 Route of Administration

13.2.1.4 Orphan Drug/Fast Track/Special Designation

13.2.1.5 Area

13.2.1.6 Type of Molecular Entity

13.3 Current Status

13.4 Drug Overview

13.5 Drug Mechanism of Action

13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

14. GLAXOSMITHKLINE PLC PRURITUS PIPELINE DETAILS

14.1 GlaxoSmithKline Plc Business Profile

14.2 GlaxoSmithKline Plc Pruritus Drug Details

14.2.1 Drug Snapshot

14.2.1.1 Originator

14.2.1.2 Collaborator/Co-Developer

14.2.1.3 Route of Administration

14.2.1.4 Orphan Drug/Fast Track/Special Designation

14.2.1.5 Area

14.2.1.6 Type of Molecular Entity

14.3 Current Status

14.4 Drug Overview

14.5 Drug Mechanism of Action

14.6 Clinical/Pre-clinical Trial Details

14.7 Latest Drug Developments

15. MENLO THERAPEUTICS INC PRURITUS PIPELINE DETAILS

15.1 Menlo Therapeutics Inc Business Profile

15.2 Menlo Therapeutics Inc Pruritus Drug Details

15.2.1 Drug Snapshot

15.2.1.1 Originator

15.2.1.2 Collaborator/Co-Developer

15.2.1.3 Route of Administration

15.2.1.4 Orphan Drug/Fast Track/Special Designation

15.2.1.5 Area

15.2.1.6 Type of Molecular Entity

15.3 Current Status

15.4 Drug Overview

15.5 Drug Mechanism of Action

15.6 Clinical/Pre-clinical Trial Details

15.7 Latest Drug Developments

16. NERRE THERAPEUTICS LTD PRURITUS PIPELINE DETAILS

16.1 NeRRe Therapeutics Ltd Business Profile

16.2 NeRRe Therapeutics Ltd Pruritus Drug Details

16.2.1 Drug Snapshot

16.2.1.1 Originator

16.2.1.2 Collaborator/Co-Developer

16.2.1.3 Route of Administration

- 16.2.1.4 Orphan Drug/Fast Track/Special Designation
- 16.2.1.5 Area
- 16.2.1.6 Type of Molecular Entity
- 16.3 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17. NEUROCYCLE THERAPEUTICS PRURITUS PIPELINE DETAILS

- 17.1 NeuroCycle Therapeutics Business Profile
- 17.2 NeuroCycle Therapeutics Pruritus Drug Details
 - 17.2.1 Drug Snapshot
 - 17.2.1.1 Originator
 - 17.2.1.2 Collaborator/Co-Developer
 - 17.2.1.3 Route of Administration
 - 17.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 17.2.1.5 Area
 - 17.2.1.6 Type of Molecular Entity
- 17.3 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18. PATARA PHARMA INC PRURITUS PIPELINE DETAILS

- 18.1 Patara Pharma Inc Business Profile
- 18.2 Patara Pharma Inc Pruritus Drug Details
 - 18.2.1 Drug Snapshot
 - 18.2.1.1 Originator
 - 18.2.1.2 Collaborator/Co-Developer
 - 18.2.1.3 Route of Administration
 - 18.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 18.2.1.5 Area
 - 18.2.1.6 Type of Molecular Entity
- 18.3 Current Status
- 18.4 Drug Overview

- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19. PEPTIDE LOGIC PRURITUS PIPELINE DETAILS

- 19.1 Peptide Logic Business Profile
- 19.2 Peptide Logic Pruritus Drug Details
 - 19.2.1 Drug Snapshot
 - 19.2.1.1 Originator
 - 19.2.1.2 Collaborator/Co-Developer
 - 19.2.1.3 Route of Administration
 - 19.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 19.2.1.5 Area
 - 19.2.1.6 Type of Molecular Entity
- 19.3 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20. RDD PHARMA LTD PRURITUS PIPELINE DETAILS

- 20.1 RDD Pharma Ltd Business Profile
- 20.2 RDD Pharma Ltd Pruritus Drug Details
 - 20.2.1 Drug Snapshot
 - 20.2.1.1 Originator
 - 20.2.1.2 Collaborator/Co-Developer
 - 20.2.1.3 Route of Administration
 - 20.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 20.2.1.5 Area
 - 20.2.1.6 Type of Molecular Entity
- 20.3 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21. SANIONA AB PRURITUS PIPELINE DETAILS

- 21.1 Saniona AB Business Profile
- 21.2 Saniona AB Pruritus Drug Details
 - 21.2.1 Drug Snapshot
 - 21.2.1.1 Originator
 - 21.2.1.2 Collaborator/Co-Developer
 - 21.2.1.3 Route of Administration
 - 21.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 21.2.1.5 Area
 - 21.2.1.6 Type of Molecular Entity
- 21.3 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

22. SANWA KAGAKU KENKYUSHO CO LTD PRURITUS PIPELINE DETAILS

- 22.1 Sanwa Kagaku Kenkyusho Co Ltd Business Profile
- 22.2 Sanwa Kagaku Kenkyusho Co Ltd Pruritus Drug Details
 - 22.2.1 Drug Snapshot
 - 22.2.1.1 Originator
 - 22.2.1.2 Collaborator/Co-Developer
 - 22.2.1.3 Route of Administration
 - 22.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 22.2.1.5 Area
 - 22.2.1.6 Type of Molecular Entity
- 22.3 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

23. SIENNA BIOPHARMACEUTICALS INC PRURITUS PIPELINE DETAILS

- 23.1 Sienna Biopharmaceuticals Inc Business Profile
- 23.2 Sienna Biopharmaceuticals Inc Pruritus Drug Details
 - 23.2.1 Drug Snapshot
 - 23.2.1.1 Originator

- 23.2.1.2 Collaborator/Co-Developer
- 23.2.1.3 Route of Administration
- 23.2.1.4 Orphan Drug/Fast Track/Special Designation
- 23.2.1.5 Area
- 23.2.1.6 Type of Molecular Entity
- 23.3 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

24. SUMITOMO DAINIPPON PHARMA CO LTD PRURITUS PIPELINE DETAILS

- 24.1 Sumitomo Dainippon Pharma Co Ltd Business Profile
- 24.2 Sumitomo Dainippon Pharma Co Ltd Pruritus Drug Details
 - 24.2.1 Drug Snapshot
 - 24.2.1.1 Originator
 - 24.2.1.2 Collaborator/Co-Developer
 - 24.2.1.3 Route of Administration
 - 24.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 24.2.1.5 Area
 - 24.2.1.6 Type of Molecular Entity
- 24.3 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

25. SUNNY PHARMTECH INC PRURITUS PIPELINE DETAILS

- 25.1 Sunny Pharmtech Inc Business Profile
- 25.2 Sunny Pharmtech Inc Pruritus Drug Details
 - 25.2.1 Drug Snapshot
 - 25.2.1.1 Originator
 - 25.2.1.2 Collaborator/Co-Developer
 - 25.2.1.3 Route of Administration
 - 25.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 25.2.1.5 Area
 - 25.2.1.6 Type of Molecular Entity

- 25.3 Current Status
- 25.4 Drug Overview
- 25.5 Drug Mechanism of Action
- 25.6 Clinical/Pre-clinical Trial Details
- 25.7 Latest Drug Developments

26. TEIKOKU PHARMA USA INC PRURITUS PIPELINE DETAILS

- 26.1 Teikoku Pharma USA Inc Business Profile
- 26.2 Teikoku Pharma USA Inc Pruritus Drug Details
 - 26.2.1 Drug Snapshot
 - 26.2.1.1 Originator
 - 26.2.1.2 Collaborator/Co-Developer
 - 26.2.1.3 Route of Administration
 - 26.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 26.2.1.5 Area
 - 26.2.1.6 Type of Molecular Entity
- 26.3 Current Status
- 26.4 Drug Overview
- 26.5 Drug Mechanism of Action
- 26.6 Clinical/Pre-clinical Trial Details
- 26.7 Latest Drug Developments

27. TESARO INC PRURITUS PIPELINE DETAILS

- 27.1 TESARO Inc Business Profile
- 27.2 TESARO Inc Pruritus Drug Details
 - 27.2.1 Drug Snapshot
 - 27.2.1.1 Originator
 - 27.2.1.2 Collaborator/Co-Developer
 - 27.2.1.3 Route of Administration
 - 27.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 27.2.1.5 Area
 - 27.2.1.6 Type of Molecular Entity
- 27.3 Current Status
- 27.4 Drug Overview
- 27.5 Drug Mechanism of Action
- 27.6 Clinical/Pre-clinical Trial Details
- 27.7 Latest Drug Developments

28. TIOGA PHARMACEUTICALS INC PRURITUS PIPELINE DETAILS

28.1 Tioga Pharmaceuticals Inc Business Profile

28.2 Tioga Pharmaceuticals Inc Pruritus Drug Details

28.2.1 Drug Snapshot

28.2.1.1 Originator

28.2.1.2 Collaborator/Co-Developer

28.2.1.3 Route of Administration

28.2.1.4 Orphan Drug/Fast Track/Special Designation

28.2.1.5 Area

28.2.1.6 Type of Molecular Entity

28.3 Current Status

28.4 Drug Overview

28.5 Drug Mechanism of Action

28.6 Clinical/Pre-clinical Trial Details

28.7 Latest Drug Developments

29. TREVI THERAPEUTICS INC PRURITUS PIPELINE DETAILS

29.1 Trevi Therapeutics Inc Business Profile

29.2 Trevi Therapeutics Inc Pruritus Drug Details

29.2.1 Drug Snapshot

29.2.1.1 Originator

29.2.1.2 Collaborator/Co-Developer

29.2.1.3 Route of Administration

29.2.1.4 Orphan Drug/Fast Track/Special Designation

29.2.1.5 Area

29.2.1.6 Type of Molecular Entity

29.3 Current Status

29.4 Drug Overview

29.5 Drug Mechanism of Action

29.6 Clinical/Pre-clinical Trial Details

29.7 Latest Drug Developments

30. VANDA PHARMACEUTICALS INC PRURITUS PIPELINE DETAILS

30.1 Vanda Pharmaceuticals Inc Business Profile

30.2 Vanda Pharmaceuticals Inc Pruritus Drug Details

- 30.2.1 Drug Snapshot
 - 30.2.1.1 Originator
 - 30.2.1.2 Collaborator/Co-Developer
 - 30.2.1.3 Route of Administration
 - 30.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 30.2.1.5 Area
 - 30.2.1.6 Type of Molecular Entity
- 30.3 Current Status
- 30.4 Drug Overview
- 30.5 Drug Mechanism of Action
- 30.6 Clinical/Pre-clinical Trial Details
- 30.7 Latest Drug Developments

31. VIVOZON INC PRURITUS PIPELINE DETAILS

- 31.1 Vivozon Inc Business Profile
- 31.2 Vivozon Inc Pruritus Drug Details
 - 31.2.1 Drug Snapshot
 - 31.2.1.1 Originator
 - 31.2.1.2 Collaborator/Co-Developer
 - 31.2.1.3 Route of Administration
 - 31.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 31.2.1.5 Area
 - 31.2.1.6 Type of Molecular Entity
- 31.3 Current Status
- 31.4 Drug Overview
- 31.5 Drug Mechanism of Action
- 31.6 Clinical/Pre-clinical Trial Details
- 31.7 Latest Drug Developments

20. LATEST PRURITUS DRUG PIPELINE DEVELOPMENTS, 2019

21. APPENDIX

- 21.1 About Us
- 21.2 Sources and Methodology
- 21.3 Contact Information

I would like to order

Product name: 2019 Future of Pruritus R&D Pipeline Drugs and Companies- Analysis of Global Pruritus Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2C0BC664989EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2C0BC664989EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

